Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Conditioning Regimens

Analysis of prognostic factors for allogeneic marrow transplantation following busulfan and cyclophosphamide in myelodysplastic syndrome and after leukemic transformation

Bone Marrow Transplantation volume 25, pages 1219–1222 (2000)Cite this article

Abstract

Prognostic factors in 42 patients aged 11 to 62 (median 46) years, with myelodysplastic syndrome (MDS) or after leukemic transformation, who underwent allogeneic marrow transplantation between 1984 and 1999 were analyzed. Thirty-six had advanced disease morphology; 19 had leukemic transformation. Twenty-nine received a preparative regimen of BuCy2 and 13 busulfan 14 mg/kg, etoposide 50 mg/kg and cyclophosphamide 120 mg/kg. Severe hepatic veno-occlusive disease (VOD) occurred in three patients all of whom received anti-leukemic chemotherapy prior to transplantation. Fifteen patients (36%) died from early transplant-related complications; nine patients relapsed. The estimated 4 year disease-free survival (DFS) was 35% (95% CI 26–44%). Older age was the most significant adverse prognostic factor. Patients with leukemic transformation who underwent early transplantation had significantly better DFS than those treated first with chemotherapy (P = 0.002). Delayed toxicity was rare in these patients; no late relapses occurred. Bone Marrow Transplantation (2000) 25, 1219–1222.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Cheson BD . The myelodysplastic syndromes: current approaches to therapy Ann Intern Med 1990 112: 932–941

    Article  CAS  Google Scholar 

  2. Anderson JE, Appelbaum FR, Fisher LD et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome Blood 1993 82: 677–681

    CAS  PubMed  Google Scholar 

  3. Anderson JE, Appelbaum FR, Storb R . An update on allogeneic marrow transplantation for myelodysplastic syndrome Leuk Lymphoma 1995 17: 95–99

    Article  CAS  Google Scholar 

  4. Anderson JE, Appelbaum FR, Schoch G et al. Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors Blood 1996 87: 51–58

    CAS  PubMed  Google Scholar 

  5. Ratanatharathorn V, Karanes C, Uberti J et al. Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes Blood 1993 81: 2194–2199

    CAS  PubMed  Google Scholar 

  6. Anderson JE, Appelbaum FR, Schoch G et al. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors J Clin Oncol 1996 14: 220–226

    Article  CAS  Google Scholar 

  7. Locatelli F, Niemeyer C, Angelucci E et al. Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: a report from the European Working Group on myelodysplastic syndrome in childhood J Clin Oncol 1997 15: 566–573

    Article  CAS  Google Scholar 

  8. Gluckberg H, Storb R, Fefer A et al. Clinical manifestation of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors Transplantation 1974 18: 295–304

    Article  Google Scholar 

  9. Shulman HM, Sale GE, Lerner KG et al. Chronic cutaneous graft-versus-host disease in man Am J Pathol 1978 19: 545–570

    Google Scholar 

  10. McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients Ann Intern Med 1993 11: 255–267

    Article  Google Scholar 

  11. Clark JG, Crawford SW, Madtes DK, Sullivan KM . Obstructive lung disease after allogeneic marrow transplantation Ann Intern Med 1989 111: 368–376

    Article  CAS  Google Scholar 

  12. Kaplan EL, Meier P . Nonparametric estimation from incomplete observations J Am Stat Assoc 1958 53: 457–481

    Article  Google Scholar 

  13. Mantel N . Evaluation of survival data and two new rank order statistics arising in its consideration Cancer Chemother Rep 1966 50: 163–170

    CAS  PubMed  Google Scholar 

  14. Cox DR . Regression models and life tables J Roy Stat Soc 1972 34: 187–220

    Google Scholar 

  15. Tutschka PJ, Copelan EA, Klein JP . Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen Blood 1987 70: 1382–1388

    CAS  PubMed  Google Scholar 

  16. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-vs-host disease after marrow transplantation for leukemia New Engl J Med 1986 313: 729–735

    Article  Google Scholar 

  17. Nevill TJ, Shepherd JD, Reece DE et al. Treatment of myelodysplastic syndrome with busulfan-cyclophosphamide conditioning followed by allogeneic BMT Bone Marrow Transplant 1992 10: 445–450

    CAS  PubMed  Google Scholar 

  18. O'Donnell MR, Long GD, Parker PM et al. Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia J Clin Oncol 1995 13: 2973–2979

    Article  CAS  Google Scholar 

  19. Clift RA, Buckner CD, Thomas ED et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide Blood 1994 84: 2036–2043

    CAS  PubMed  Google Scholar 

  20. Copelan E, Deeg J . Conditioning for allogeneic marrow transplantation in patients with lymphohematopoietic malignancies without the use of total body irradiation Blood 1992 80: 1648–1658

    CAS  PubMed  Google Scholar 

  21. Styler MJ, Crilley P, Biggs J et al. Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective multi-center analysis Bone Marrow Transplant 1999 18: 171–176

    Google Scholar 

  22. Copelan EA, Kapoor N, Berliner M, Tutschka PJ . Bone marrow transplantation without total body irradiation in patients 40 and older Transplantation 1989 48: 65–68

    Article  CAS  Google Scholar 

  23. Copelan E, Penza S, Theil K et al. Allogeneic marrow transplantation with BuCy2 in patients with chronic myelogenous leukemia Blood 1998 92: 285a

    Google Scholar 

  24. Blaise D, Maraninchi D, Archimbaud E et al. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Groupe d'Etudes de la Greffe de Moelle Osseuse Blood 1992 79: 2578–2582

    CAS  PubMed  Google Scholar 

  25. Ringden O, Ruutu T, Remberger M et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplant Group Blood 1994 83: 2723–2730

    CAS  PubMed  Google Scholar 

  26. Copelan EA, Biggs JC, Thompson JM et al. Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2 Blood 1991 78: 838–843

    CAS  PubMed  Google Scholar 

  27. Ringden O, Remberger M, Ruutu T et al. for the Nordic Bone Marrow Transplantation Group Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia Blood 1999 93: 2196–2201

    CAS  PubMed  Google Scholar 

  28. Copelan EA . Are busulfan-based preparative regimens equivalent, worse, or better than total body irradiation regimens? In: Bolwell BJ (ed) Current Controversies in Bone Marrow Transplantation Humana Press: Clifton, NJ 2000 pp53–67

    Chapter  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bone Marrow Transplantation Program, Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University Medical Center, Columbus, Ohio, USA

    EA Copelan, SL Penza, PJ Elder, SA Ezzone, MD Scholl, PS Belt & BR Avalos

  2. Department of Pharmacy, Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University Medical Center, Columbus, Ohio, USA

    TP Bechtel

Authors
  1. EA Copelan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. SL Penza
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. PJ Elder
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. SA Ezzone
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. MD Scholl
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. TP Bechtel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. PS Belt
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. BR Avalos
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Copelan, E., Penza, S., Elder, P. et al. Analysis of prognostic factors for allogeneic marrow transplantation following busulfan and cyclophosphamide in myelodysplastic syndrome and after leukemic transformation. Bone Marrow Transplant 25, 1219–1222 (2000). https://doi.org/10.1038/sj.bmt.1702432

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702432

Keywords

Search

Advanced search

Quick links